Hydrogen chloride

Globex Acquires Gold Exploration Target in Arizona, USA

Retrieved on: 
Thursday, March 21, 2024
Dorado, B-68, Element, Gneiss, Perchloric acid, Geo, Silver, Vein, B-29, ICP-OES, Hydrogen chloride, AAL, Salt, Gold, GMX, Toronto Stock Exchange, HF, B-34, B-19, HNO3, Glass, H3BO3, Linearity, B-47, Mining

The project area is at the northernmost margin of the historic Gold Basin Mining District.

Key Points: 
  • The project area is at the northernmost margin of the historic Gold Basin Mining District.
  • In the area covered by Globex’s Salt Spring property Globex has identified 14 small mine workings and at least 15 prospects.
  • Globex already carried out preliminary fieldwork including geological mapping and collected a total of 70 rock samples.
  • Obtained gold values above 10 g/t were re-analyzed via fire assay of a 30 g subsample and gravimetric determination.

Tonix Pharmaceuticals Announces Selection of Two Contract Manufacturing Organizations for the Launch and Commercial Manufacture of Tonmya™ for the Management of Fibromyalgia

Retrieved on: 
Wednesday, March 20, 2024
Fibromyalgia, Partnership, Patient, Tablet, Hydrogen chloride, NDA, Tonix Pharmaceuticals, Fatigue, Food, CMOS, Pharmaceutical industry

CHATHAM, N.J., March 20, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced it has selected two contract manufacturing organizations (CMOs), one of which is Almac Pharma Services, a member of the privately owned Almac Group, as dual supply sources for the potential launch and commercialization of Tonmya™ (also known as TNX-102 SL, cyclobenzaprine HCl sublingual tablets) in the U.S.

Key Points: 
  • As previously announced, Tonix’s second positive Phase 3 study, RESILIENT, met its pre-specified primary endpoint, significantly reducing daily pain compared to placebo (p=0.00005) in participants with fibromyalgia.
  • Statistically significant and clinically meaningful results (p=0.001 or better) were also seen in all key secondary endpoints related to improving sleep quality, reducing fatigue, and improving overall fibromyalgia symptoms and function.
  • TNX-102 SL was well tolerated with an adverse event profile comparable to prior studies, and no new safety signals were observed.
  • Tonix plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration in the second half of 2024 for Tonmya for the management of fibromyalgia.

Tonix Pharmaceuticals Announces Transition to Fully Integrated Biopharmaceutical Company Expected on April 1, 2024

Retrieved on: 
Tuesday, March 19, 2024
Quality control, Fibromyalgia, Tablet, Hydrogen chloride, Acquisition, Commercial, Tonix Pharmaceuticals, Therapy, Marketing, FDA, Sumatriptan, Food, Pharmaceutical industry

CHATHAM, N.J., March 19, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that it will achieve its goal of transitioning to a fully integrated pharmaceutical company on April 1, 2024. Since the acquisition of Zembrace® SymTouch® (sumatriptan injection) 3 mg and Tosymra® (sumatriptan nasal spray) 10 mg on June 30, 2023, Tonix Pharmaceuticals has been putting in place the personnel, systems and contracts required to support a commercial organization. Both products are indicated for the treatment of acute migraine with or without aura in adults.

Key Points: 
  • Zembrace® SymTouch® and Tosymra® will be marketed by Tonix Medicines, Tonix’s wholly-owned commercial subsidiary
    Commercial capabilities prepare Tonix for the potential launch in 2025 of Tonmya™ for the management of fibromyalgia, assuming FDA approval
    CHATHAM, N.J., March 19, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that it will achieve its goal of transitioning to a fully integrated pharmaceutical company on April 1, 2024.
  • Since the acquisition of Zembrace® SymTouch® (sumatriptan injection) 3 mg and Tosymra® (sumatriptan nasal spray) 10 mg on June 30, 2023, Tonix Pharmaceuticals has been putting in place the personnel, systems and contracts required to support a commercial organization.
  • Both products are indicated for the treatment of acute migraine with or without aura in adults.
  • “Tonix will become a fully integrated biopharmaceutical company with a mission of developing and marketing innovative, high-value therapeutics,” said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals.

Purdue Pharma L.P. Awards Grant for Investigator-initiated Research to Examine Opioid Overdose Reversal Using Nalmefene HCl Injection

Retrieved on: 
Wednesday, March 27, 2024
Other Health, Research, General Health, Pharmaceutical, University, Education, Clinical Trials, Science, Biotechnology, FDA, Other Science, Health, Hypoventilation, Hypersensitivity, Nalmefene, IIR, Pulmonary edema, Doctor of Pharmacy, University of New Mexico, Safety, Tachycardia, Risk, Patient, Hydrogen chloride, Purdue Pharma, Naloxone, UNM, Emergency medicine, Ventricular tachycardia, Mortality, Buprenorphine, MD, Methadone, Emergency department, Ventricular fibrillation, Hypotension, Oxygen, HCI, ED, Hypertension, Recurrence, LAAM, Opioid overdose, Purdue University, Pharmaceutical industry

“We are enthusiastic about supporting research that can contribute to addressing the opioid overdose crisis.”

Key Points: 
  • “We are enthusiastic about supporting research that can contribute to addressing the opioid overdose crisis.”
    The prospective, randomized study, “Evaluation of Nalmefene HCl Injection for Recurrent Respiratory Depression After Suspected Acute Opioid Overdose in an Emergency Department,” will compare the efficacy and safety of nalmefene HCl injection to naloxone injection in the treatment of recurrent respiratory depression due to opioid overdose.
  • Nalmefene HCl injection is an opioid antagonist indicated for the complete or partial reversal of opioid drug effects, including respiratory depression, induced by either natural or synthetic opioids and in the management of known or suspected opioid overdose.
  • Nalmefene Hydrochloride injection is contraindicated in patients with a known hypersensitivity to the product.1 The Company distributes nalmefene HCl injection for no profit.
  • The study will be independently developed and carried out by UNM’s research team with Purdue Pharma providing only funding and nalmefene HCI injection.

Hydrochloric Acid Market Size to Grow by USD 978.77 million, 5.72% YOY market growth in 2023-2024, Technavio

Retrieved on: 
Thursday, March 14, 2024
Carbon, Resin, Chlorine, PVC, Hydrochloric acid, BASF, Growth, Occidental Petroleum, Olin Corporation, Steel, Tessenderlo Group, COVID-19, Hydrogen chloride, Alkyl polyglycoside, APG, Food, Synthetic, AGC, Fructose, Merck Group, HFCS, Mining, Hazardous waste, Chemistry, Drink, Vinyl chloride, Optimism, Ground substance, USD, SGL Carbon, PCC, Palladium

The food segment, valued at USD 689.47 million in 2018, drives significant growth in the hydrochloric acid market.

Key Points: 
  • The food segment, valued at USD 689.47 million in 2018, drives significant growth in the hydrochloric acid market.
  • The report provides actionable insights and estimates the contribution of all regions to the growth of the global hydrochloric acid market.
  • Expansion of hydrochloric acid facilities, like SGL Carbon's unit delivery to Travancore-Cochin Chemicals Ltd., drives market growth, enabling companies to enhance their market presence and offer a wider product range, boosting the global hydrochloric acid market.
  • Substitutes like emerald-safe acid, phosphoric acid, sodium bisulfate, and trisodium phosphate pose challenges to hydrochloric acid market growth.

Lion One Provides Update on Tuvatu Operations in Fiji

Retrieved on: 
Monday, March 4, 2024
Diamond, LIMS, ALS, PQ, Mining, NQ, News, HQ, MAIG, Qualified person (European Union), Hydrogen chloride, Gold, Laboratory information management system, AA, ASX, Element, National instrument, Pathfinder, QAQC, HF, Zone 2, ICP-AES, ICP-OES, CIL

North Vancouver, British Columbia--(Newsfile Corp. - March 4, 2024) - Lion One Metals Limited (TSXV: LIO) (OTCQX: LOMLF) (ASX: LLO) ("Lion One" or the "Company") is pleased to provide an update on ongoing operations at the company's 100% owned Tuvatu Alkaline Gold Project in Fiji.

Key Points: 
  • North Vancouver, British Columbia--(Newsfile Corp. - March 4, 2024) - Lion One Metals Limited (TSXV: LIO) (OTCQX: LOMLF) (ASX: LLO) ("Lion One" or the "Company") is pleased to provide an update on ongoing operations at the company's 100% owned Tuvatu Alkaline Gold Project in Fiji.
  • The Tuvatu project is currently in the pilot plant stage of operations.
  • The focus of mining operations to date has been on the development of underground access.
  • Diamond drill core samples are logged and split by Lion One personnel on site and delivered to the Lion One Laboratory for preparation and analysis.

Tonix Pharmaceuticals Reports Improvement in “Brain Fog,” in Fibromyalgia Patients Treated with Tonmya™ in RESILIENT, an NDA-Enabling Phase 3 Clinical Trial, at the 6th International Congress on Controversies in Fibromyalgia

Retrieved on: 
Monday, March 11, 2024
Blood pressure, Tonix Pharmaceuticals, Woman, New Drug Application, FDA, Pain, Food, Sleep, Hope, Hydrogen chloride, FIQ, Human, Fatigue, Weight gain, Patient, Tablet, Insomnia, NDA, Brain, DSM-IV codes, Pharmaceutical industry

CHATHAM, N.J., March 11, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced the presentation of additional efficacy data from RESILIENT, the second positive Phase 3 study evaluating Tonmya (also known as TNX-102 SL, cyclobenzaprine HCl sublingual tablets) for the management of fibromyalgia, at the 6th International Congress on Controversies in Fibromyalgia in Brussels, Belgium, March 7-8, 2024.

Key Points: 
  • We now report that the effect sizes of the five continuous key secondary outcomes measures ranged from 0.3 to 0.5.
  • The FIQ-R cognitive item showed nominal improvement in Tonmya-treated patients vs placebo-treated patients with a p=0.001 and effect size of 0.31.
  • RELIEF, the first Phase 3 trial of Tonmya 5.6 mg in fibromyalgia, was completed in December 2020.
  • We also believe the favorable tolerability and side effect profiles will be important to patients and doctors managing this debilitating condition on a long-term basis.”

Tonix Pharmaceuticals Selects EVERSANA® to Support Launch Strategy and Commercialization Planning of Tonmya™ for the Management of Fibromyalgia

Retrieved on: 
Wednesday, March 6, 2024
Therapy, Fibromyalgia, Tonix Pharmaceuticals, New Drug Application, FDA, Food, Hydrogen chloride, Fatigue, Patient, Tablet, Pharmaceutical industry

CHATHAM, N.J., March 06, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, announced today that EVERSANA®, a leading provider of commercialization services to the global life sciences industry, has been selected to support the launch strategy and commercial planning of Tonmya (also known as TNX-102 SL, cyclobenzaprine HCl sublingual tablets) in the U.S. Specifically, EVERSANA will work with Tonix to assess the fibromyalgia landscape and help plan an efficient go-to-market strategy.

Key Points: 
  • Specifically, EVERSANA will work with Tonix to assess the fibromyalgia landscape and help plan an efficient go-to-market strategy.
  • “EVERSANA shares our commitment to delivering novel therapeutics to patients in need,” said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals.
  • “We are excited to further refine our business strategy for the anticipated launch of Tonmya in 2025.
  • As previously announced, Tonix’s second positive Phase 3 study, RESILIENT, met its pre-specified primary endpoint, significantly reducing daily pain compared to placebo (p=0.00005) in participants with fibromyalgia.

Globex Acquires Gold Silver Exploration Target in Nevada, USA

Retrieved on: 
Wednesday, February 28, 2024
Quartz, Double standard, Copper, Mining, Peak, GMX, Toronto Stock Exchange, Hydrothermal circulation, HNO3, Horizontal, Hydrogen chloride, Gold, Crescent, Geo, Rest, Lead, Element, C-9, H3BO3, The Red Star, Perchloric acid, AAL, Red star, HF, Silver, ICP-OES, R-40, C-3, AG

Most of the historic production included turquoise (around the porphyry copper occurrence at Crescent Peak), gold, silver, copper and lead.

Key Points: 
  • Most of the historic production included turquoise (around the porphyry copper occurrence at Crescent Peak), gold, silver, copper and lead.
  • In the early 1980’s the Crescent Mining Ltd. exploited the Rest Mine and extracted gold via a heap leach operation.
  • Initial historic mining and exploration at the Red Star vein system dates back to the period 1907-1914.
  • Obtained gold values above 10 ppm and silver above100 ppm were re-analyzed via fire assay of a 30 g subsample and gravimetric determination.

Tonix Pharmaceuticals Announces Positive Results from Clinical Pharmacokinetic Bridging Study of Tonmya™ to Support Development and Partnering in Japan and China

Retrieved on: 
Tuesday, February 27, 2024
Fibromyalgia, Tonix Pharmaceuticals, Investigational New Drug, New Drug Application, Marketing, Female, Hydrogen chloride, Data, PMDA, Patient, Male, Tablet, IND, NDA, NMPA, CTN, NCE, Pharmaceutical industry

CHATHAM, N.J., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, announced positive results from its clinical pharmacokinetic (PK) bridging study of Tonmya™ (also known as TNX-102 SL, cyclobenzaprine HCl sublingual tablets) in healthy adult male and female ethnic Japanese and Chinese volunteers. Results indicate that key pharmacokinetic parameters of cyclobenzaprine are comparable in ethnic Japanese and Chinese volunteers to Caucasian volunteers from a prior PK study. Tonmya was generally well tolerated in the ethnic Japanese and Chinese healthy volunteers. The company expects these data to fulfill the requirement for a bridging study, and to support regulatory filings for clinical studies in Japan and China where cyclobenzaprine is a new chemical entity (NCE). Tonix holds issued patents for market exclusivity rights of Tonmya in Japan, China, Hong Kong and Taiwan.

Key Points: 
  • Results indicate that key pharmacokinetic parameters of cyclobenzaprine are comparable in ethnic Japanese and Chinese volunteers to Caucasian volunteers from a prior PK study.
  • The company expects these data to fulfill the requirement for a bridging study, and to support regulatory filings for clinical studies in Japan and China where cyclobenzaprine is a new chemical entity (NCE).
  • Tonix holds issued patents for market exclusivity rights of Tonmya in Japan, China, Hong Kong and Taiwan.
  • “This bridging study is an important first step as we begin evaluating the potential for approval and marketing Tonmya in Japan and China.